By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
AgomAb Therapeutics NV insiders have been one-way buyers this past year: three people put roughly $311,000 into the stock and nobody sold with their own money.
Knotnerus Tim Jasper (CEO) made the biggest buy, worth around $51,000. That includes C-suite money, which tends to get the most attention.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. This quarter so far: net buying. 34 investment managers listed AGMB in their latest 13F filings (Q2 2026); funds were split between buying and selling.
Are insiders buying or selling AGMB stock?
In the last 12 months AgomAb Therapeutics NV insiders made open-market purchases worth about $311,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in AGMB?
The most recent open-market insider trade in AGMB was filed on 2026-10-09.
How many institutions own AGMB?
34 investment managers reported holding AGMB in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded AGMB?
No congressional trades in AGMB were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).